Redcare Pharmacy (Shop Apoth) stock (NL0012044747): Strong growth momentum after Q1 update

Redcare Pharmacy (Shop Apoth) has raised its 2026 guidance after reporting strong growth in its Q1 2025 trading update, keeping the online pharmacy in focus for European and US investors watching digital health trends.

Redcare Pharmacy (Shop Apoth) has come back into focus after a strong trading update for the first quarter of 2025 and a subsequent increase in its 2026 guidance, underscoring the momentum in its European online pharmacy platform, according to a company release dated 04/16/2025 and follow-up commentary on 04/17/2025 by Euronext Amsterdam.

As of: 05/15/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Redcare Pharmacy
• Sector/industry: Online pharmacy, e-commerce healthcare
• Headquarters/country: Amsterdam, Netherlands
• Core markets: Germany, France, Italy, other EU markets
• Key revenue drivers: Online prescription and OTC drug sales, marketplace health products
• Home exchange/listing venue: Euronext Amsterdam (ticker: RDC)
• Trading currency: EUR

Redcare Pharmacy: core business model

Redcare Pharmacy, formerly known under the Shop Apotheke brand, operates a large online pharmacy and health products platform focused on continental Europe, with a particular emphasis on the German-speaking and Benelux markets. The company ships prescription medicines, over-the-counter (OTC) drugs, and a wide range of wellness products directly to consumers.

The company follows a pure-play digital model, relying on central warehouses and logistics partners instead of a network of physical pharmacy branches. This allows Redcare Pharmacy to scale volumes and offer a broad assortment online while aiming for cost efficiency and high order throughput, according to its company profile and investor materials updated in 2024.

A key element of the business is the integration of prescription processing, including electronic prescriptions in Germany, where regulatory changes have opened the market for digital players in recent years. Redcare Pharmacy’s ability to capture e-prescription volumes is central to its long-term growth path, based on the company’s strategic descriptions in its 2024 annual report published in March 2025.

Beyond pure drug delivery, Redcare Pharmacy also positions itself as a broader healthcare platform, offering personal care, wellness, beauty, and medical devices. This diversification reduces dependency on any single reimbursement regime and exposes the company to consumer health trends, as indicated in the 2024 annual results communication released on 03/06/2025.

Main revenue and product drivers for Redcare Pharmacy

Redcare Pharmacy’s revenue mix is driven by both prescription drugs and non-prescription categories such as OTC medicines, vitamins, supplements, and personal care products. In its 2024 annual results, the company reported strong revenue growth supported by rising order frequencies and an expanding active customer base, according to the annual report published on 03/06/2025 on the company website and on Euronext Amsterdam.

The first quarter of 2025 confirmed this trend. In its Q1 2025 trading update released on 04/16/2025, Redcare Pharmacy reported continued double-digit revenue growth compared with the prior-year quarter, driven by higher volumes in Germany and international markets. The company also highlighted an improvement in adjusted EBITDA, reflecting scale effects and ongoing cost discipline, according to Redcare Q1 2025 trading update as of 04/16/2025.

Following this update, Redcare Pharmacy raised its mid-term 2026 guidance, indicating it now expects higher revenues and a better adjusted EBITDA margin than previously communicated. This upgraded outlook was cited by several financial news outlets and the Euronext exchange as a key reason for renewed interest in the stock, according to Euronext Amsterdam note as of 04/17/2025.

Another important driver is the company’s marketplace offerings, where third-party brands can distribute health and wellness products through the Redcare platform. This asset-light revenue stream allows the company to broaden its assortment without fully bearing inventory risk, while also benefiting from commission income and higher basket values, as described in management’s 2024 strategy update published in March 2025.

Customer acquisition and retention play a crucial role in sustaining growth. Redcare Pharmacy invests in digital marketing, loyalty programs, and user-friendly app and web interfaces to keep customers within its ecosystem. Management has emphasized that repeat orders from returning customers represent a significant portion of sales, which helps support gross margin stability, according to the 2024 results presentation dated 03/06/2025.

Industry trends and competitive position

The European online pharmacy market has been expanding on the back of demographic change, growing acceptance of telemedicine, and the gradual digitalization of prescription processes. In Germany, one of Redcare Pharmacy’s key markets, the introduction of electronic prescriptions has been a structural driver for online dispensing, as reflected in industry data from 2023 and 2024 cited by the company in its investor updates.

Competition remains intense, with rivals including other large European online pharmacies and traditional brick-and-mortar chains that are expanding their digital capabilities. Redcare Pharmacy aims to differentiate itself through scale, logistics efficiency, assortment breadth, and customer service. Management has highlighted that its scale in Germany and selected EU markets gives it purchasing leverage with suppliers and manufacturers, according to commentary in the 2024 annual report published in March 2025.

Regulation is another important dimension of the competitive landscape. Online supply of prescription medicines is strictly regulated across Europe, and companies must comply with national and EU-level rules on pharmacy licensing, data protection, and cross-border shipments. Redcare Pharmacy operates licensed pharmacies in the EU to fulfill orders, and regulatory compliance remains a central element of its business model, as outlined in its 2024 risk report issued together with the annual results.

At the same time, the digitalization of healthcare services and the rise of telehealth platforms create opportunities for deeper integration between online consultations and medicine delivery. Redcare Pharmacy has signaled interest in partnerships and integrations in this area, although the exact scope and financial contribution of such initiatives remain to be seen and were not quantified in detail in the Q1 2025 update.

Why Redcare Pharmacy matters for US investors

For US investors, Redcare Pharmacy offers exposure to the European digital health and e-pharmacy market, which differs in structure and regulation from the US but is driven by similar macro trends such as aging populations and increased use of online services. The stock trades on Euronext Amsterdam under the ISIN NL0012044747, making it accessible via many international brokerage platforms that cater to US-based clients.

Although Redcare Pharmacy’s core revenue base is in Europe, changes in global interest rates, FX movements between the euro and the US dollar, and investor appetite for growth-oriented e-commerce names can all influence sentiment around the stock. For globally diversified portfolios, the company can function as a thematic play on European digital healthcare infrastructure rather than a direct bet on US healthcare policy.

Some US investors may also look at Redcare Pharmacy as part of a broader comparison with US-listed online health and pharmacy players. While business models and reimbursement frameworks differ, trends in customer adoption, margins, and logistics efficiency in Europe can offer context for evaluating digital health strategies across regions. The company’s updates are therefore watched beyond its domestic investor base, particularly when guidance is raised or when regulatory changes affect its addressable market.

Conclusion

Redcare Pharmacy (Shop Apoth) has underlined its growth ambitions with a solid Q1 2025 trading update and a higher 2026 guidance, reinforcing its position as a key player in Europe’s online pharmacy market. The combination of expanding e-prescription usage, a broadening non-prescription portfolio, and marketplace activities provides multiple levers for revenue development. At the same time, the company remains exposed to regulatory shifts, competitive dynamics, and execution risks in logistics and customer acquisition. For internationally oriented investors, including those in the US, Redcare Pharmacy represents a focused exposure to European digital health and e-commerce trends, and upcoming quarterly updates and regulatory developments in core markets such as Germany are likely to remain important catalysts for the stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.